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ABSTRACT 
 
Background: Patients with acute coronary syndrome (ACS) may present with a 
wide range of symptoms that may easily be misdiagnosed.  
Methods: This cross-sectional, hospital-based, descriptive, retrospective audit of 
medical records was based at the Ladysmith Provincial Hospital ED and consisted of 
the last 160 consecutive patients (from the date of initiation of data collection) with 
accessible medical records and with a final hospital discharge diagnosis of ACS. 
Results: The frequency of patients presenting with ACS was approximately 53 
patients per annum.  There was a male to female ratio of 1.3: 1. The mean age was 
55.8 years (SD 12.8 years). The study population consisted of Asian (103/160, 
64.4%), black (36/160, 22.5%) and white (21/160, 13.1%). The majority of the study 
patients were unemployed (98/160, 61.25%), urban resident (143/160, 89.4%), not 
alcohol users (137/160, 85.6%), and not smokers (88/160, 55.0%). Risk factors and 
comorbidity included previous acute coronary syndrome (44/160, 27.5%), family 
history (29/160, 18.1%), previous cardiovascular surgery (10/160, 6.25%), obesity 
(45/160, 28.1%), hypercholesterolemia (49/160, 30.6%), diabetes (42/160, 26.25%), 
hypertension (76/160, 47.5%), and renal failure (27/160, 16.9%). Approximately 
three quarters (119/160, 74.4%) of the study patients had typical chest pain, 16.3% 
(26/160) had atypical chest pain, and 9.4% (15/160) had no chest pain. The median 
length of hospital stay was 3 days and the in-hospital mortality was 8.1 % (13/160).   
Conclusion: The relatively high frequency of ACS reported in this study, when 
compared to other similar studies, is concerning. Also of concern in this study, is the 
alarming proportion of Asians that presented with ACS. 
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CHAPTER 1
INTRODUCTION 
 
1.1 Background and significance of the study 
 
Acute coronary syndrome (ACS) refers to a spectrum of clinical events that result 
from acute myocardial ischaemia. It encompasses unstable angina (UA), ST- 
segment elevation myocardial infarction (STEMI), and non ST-segment elevation 
myocardial infarction (NSTEMI).1 Typically, these clinical entities are accompanied 
by cardiac ischaemic chest pain with electrocardiographic (ECG) changes and/or a 
rise in serum cardiac biomarkers.2  
 
Acute coronary syndrome may be typical or atypical.3 Potential ACS patients present 
with a wide range of symptoms of which chest pain is the chief complaint.4 ACS has 
various clinical manifestations.3 In its atypical presentation, it frequently presents 
with symptoms other than chest pain3 such as non-pain equivalent symptoms, or it 
may be silent.5,6 Early recognition of atypical ACS presentation, especially when 
chest pain is absent, presents a real challenge4 which may result in under-diagnosis 
or missed diagnosis,3 and therefore may delay initiation of appropriate treatment. 
Delay in the onset of appropriate therapy has been associated with poor outcomes.7 
 
According to the World Health Organisation (WHO), cardiovascular diseases (CVD) 
cause 12 million deaths throughout the world each year.8 Cardiovascular diseases 
remain the leading cause of death in the United States of America (USA), causing 
more than 710,000 deaths anually.9 Up to one third of patients with confirmed 
myocardial infarction present without chest discomfort (atypical presentation) in the 
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USA.1 In some low / middle-income countries, cardiovascular disease has also been 
reported as the leading cause of mortality, with ischaemic heart disease related 
mortality expected to increase by 120% for women and 137% for men by 2020.10  
 
The decision as to the most appropriate disposition (e.g. observation, referral, 
admission, discharge, follow up etc.) of patients suspected with ACS is one of the 
most challenging decisions in the emergency department (ED). Inappropriate 
disposition of patients may impact on morbidity, mortality, cost and ED overcrowding.  
 
South Africa is a low / middle-income country in which modernization and 
industrialization has resulted in an epidemiologic transition in disease patterns from 
infectious disease as the predominant cause of morbidity and mortality to more 
chronic illnesses such as heart disease.11 As a result of change in diet, decreased 
physical activity and increased tobacco use,11 cardiovascular disease is expected to 
become the leading cause of death in emerging countries including South Africa by 
2020.10 In South Africa the annual incidence of AMI is more than 800,000. 
Approximately 200,000 die acutely, half of them before reaching hospital.12 
  
In addition to the epidemiological transition,11 SA is faced with the HIV/AIDS 
pandemic which is associated with an increased risk for cardiovascular disease.13 
South Africa is the Sub-Saharan country housing the largest population living with 
HIV worldwide,13 with 6.4 million HIV infected individuals reported in the 2013 
UNAIDS report.14 Moreover, antiretroviral therapy (ART) by supposedly increasing 
the life expectancy of HIV infected individuals may further increase the incidence of 
cardiovascular diseases in South Africa.13 
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Early recognition of patients with ACS and in particular its atypical presentation 
represents a real challenge. Since time is muscle, early diagnosis and treatment will 
result in improved outcomes.2,7 
 
Acute coronary syndrome (ACS) is a common cause for admission at the Ladysmith 
Provincial Hospital. ACS accounts for up to 15% of cardiac patients admitted to the 
Ladysmith Provincial Hospital (unpublished hospital registry). However, no study has 
been conducted looking at the profile of adult patients presenting with ACS to the 
Ladysmith Provincial Hospital. 
 
This study provides insights with regard to the clinical profile of patients presenting 
with ACS to the Ladysmith Provincial Hospital, with a view to improving early, prompt 
diagnosis and clinical outcomes, and decreasing the likelihood of missed diagnosis. 
 
1.2 The aim of the study   
 
To determine the clinical profile of patients that presented to the Ladysmith 
Provincial Hospital ED and had a final hospital discharge diagnosis of ACS. 
 
1.3 Objectives  
 
1. To determine the frequency of patients that presented to the Ladysmith 
Provincial Hospital ED with a final hospital discharge diagnosis of ACS. 
2. To describe the presenting features (vital signs, typical chest pain, atypical chest 
pain, non-pain equivalent or silent, associated symptoms, cardiac failure, 
cardiogenic shock, ECG findings, laboratory findings, etc.) of patients that 
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presented to the Ladysmith Provincial Hospital ED with a final hospital discharge 
diagnosis of ACS. 
3. To describe risk factors (e.g. age, sex, race, obesity, hypertension, diabetes, 
renal failure, etc.) of patients that presented to the Ladysmith Provincial Hospital 
ED with a final hospital discharge diagnosis of ACS.    
4. To describe the initial and definitive management of patients that presented to 
the Ladysmith Provincial Hospital ED with a final hospital discharge diagnosis of 
ACS. 
5. To determine the short-term outcomes of patients that presented to the 
Ladysmith Provincial Hospital ED with a final hospital discharge diagnosis of 
ACS: clinical deterioration requiring ICU, length of hospital stay, time to clinical 
stability and death.  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 The frequency of ACS / MI internationally and in SA 
 
According to the American Heart Association 2013 statistical update which is based 
on 2009 death rate data in the United States of America (USA), more than 2150 
Americans die of coronary vascular disease daily (about 1 death every 40 seconds). 
About 153 000 Americans who died of coronary vascular disease were <65 years of 
age and 34% of deaths attributable to CVD occurred before the age of 75 years, 
which is well before the average life expectancy of 78.5 years. Coronary heart 
disease alone caused ≈1 of every 6 deaths. Each year an estimated ≈635 000 
Americans have a new coronary attack, ≈280 000 have a recurrent attack and an 
estimated 150 000 silent first myocardial infarctions occur each year. Approximately 
every 34 seconds, 1 American has a coronary event, and approximately every 1 
minute, an American will die of one. 15 In Europe, the annual incidence of ACS is 
estimated as 3 per 1000 inhabitants, but varies from country to country.16 In the 
United Kingdom (UK), the incidence of MI is approximately 2 per 1000 for women 
and 6 per 1000 for men aged 30 to 69 years.17 
 
Cardiovascular diseases are expected to become the leading cause of death in   
emerging countries including South Africa by 2020.10 In South Africa over 800,000 
people suffer from AMI every year of which 200,000 die, half of them before reaching 
the hospital.12 In low to middle income countries such as South Africa, coronary 
artery disease (CAD) accounts for approximately 10% of healthy life years lost.18  
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Prior to the era of the coronary care unit, in-hospital mortality of MI and ACS was 
estimated to be 25 - 30% worldwide. Subsequent to the introduction of coronary care 
units, the mortality decreased to approximately 16%.19 With advances in coronary 
revascularisation techniques, the current mortality is around 5% - 6%.12  
 
2.2 The burden of ACS 
 
The economic costs of ACS are huge.20 The clinical and socio-economic implications 
of this disabling disease continue to increase as the prevalence of atherosclerosis 
continue to rise worldwide.21 The estimates for economic costs of coronary heart 
disease include not only the direct cost to the health care system but also include 
loss of productivity and the continual need of formal and informal long term care.20  
 
In 1999 for instance, the economic burden of coronary heart disease in the UK was 
estimated at 2.6 billion Euros for direct health care costs, a further 3.6 billion Euros 
for the provision of care for coronary artery disease subjects and 4.4 billion for loss 
of productivity.20   In the USA, the direct and indirect cost related to the burden of 
coronary artery diseases was estimated to be more than 165 billion dollars annually.4       
 
The significant morbidity and mortality associated with missed ACS may result in 
legal action against health care providers.4 The world has not yet recovered from the 
2008 economic recession which has compelled most governments worldwide to cut 
social expenditures (including the health care expenditure) and implement cost-
effective measures. The challenge for the clinician is to balance clinical judgement, 
appropriate diagnostic strategies and evidence-based principles whilst at the same 
time avoiding unnecessary costly therapy.4  
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2.3 The impact of age on ACS 
 
Elderly individuals are at higher risk of developing ACS. Consistent study reports 
have concluded that older patients have an increased prevalence of multiple risk 
factors such as a history of angina, transient ischemic attack, stroke, MI, diabetes, 
hypertension, congestive heart failure, CABG (coronary bypass graft) surgery, and 
atrial fibrillation. Hypertension is closely related to age and is an important risk factor 
for the development of ACS in older patients. Some studies have shown that 
cigarette smoking is the only factor among traditional risk factors to be inversely 
related to age. This suggests that smoking may not be an important risk factor for 
ACS in elderly patients or cigarette smoking may be associated with a shorter 
survival and earlier onset ACS. Elderly patients commonly delay seeking medical 
care. This may be due to cognitive impairment, atypical clinical presentation or the 
presence of comorbidities that may mask a diagnosis of ACS.22 
  
ST- segment elevation myocardial infarction (STEMI) is more common in young 
patients and NSTEMI is more common in elderly patients. The higher prevalence of 
NSTEMI in the elderly may be explained by the higher prevalence of previous MI, 
multivessel disease, hypertension and ventricular hypertrophy, which may cause 
global subendocardial ischemia and poor myocardial perfusion.22 
 
Cardiovascular and bleeding events are more common among the elderly. Hospital 
mortality is also higher among the elderly even after adjusting for confounders. 
Advanced age is an independent predictor of increased risk of cardiovascular events 
in patients with ACS.22 
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2.4 The impact of sex on ACS 
 
Coronary artery disease (CAD) is the leading cause of mortality in both men and 
women in high-income countries, but women tend to experience CAD almost a 
decade later in their life.23 Men more commonly present with acute myocardial 
infarction (AMI) or sudden death, whereas women are more prone to present with 
atypical symptom and angina.24  
 
From a pathological point of view, men presenting with ACS are more likely to have 
plaque rupture, whereas artherosclerotic plaque erosions is more common in 
women.23 This implies that sex may influence plaque formation, plaque vulnerability 
and clinical presentation. Virmani et al demonstrated that fibroatheromas with a thin 
fibrous cap and a large necrotic core are more susceptible to plaque rupture and 
subsequent thrombosis than other phenotypic lesions.25 Patients presenting with 
plaque erosion usually have an indolent period of angina in contrast to those with 
plaque rupture who present more suddenly.24   
 
Analysis from the PROSPECT study has demonstrated that in spite of being older 
and having more comorbid risk factors, women diagnosed with ACS have less 
extensive CAD when compared to men. Several studies, including the PROSPECT 
study, have found that women presenting with ACS are substantially older than men, 
have more comorbid conditions such as diabetes and are more prone to increased 
risk of coronary events.23 Several other studies have also reported that men have 
more extensive atherosclerosis than women.25  
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Women with risk factors such as diabetes and hypertension develop severe 
atherosclerotic lesions at least seven to eight years later when compared with their 
male counterpart.23 This may be consistent with the theory suggesting that oestrogen 
may delay plaque development, stabilize existing plaques, and prevent plaque 
rupture in women.26  
 
2.5 The impact of race on ACS 
 
Most of the burden of cardiovascular disease mortality and morbidity is associated 
with modifiable risk factors.27,28 Differences in the prevalence and incidence of risk 
factors by race or ethnic group are substantial.29 Studies have demonstrated 
important ethnic-specific variations in risk factors, management and outcomes 
associated with atherothrombotic disease.21  
 
The rates of obesity are lower in Asians, but do not translate into lower rates of other 
comorbid conditions including diabetes mellitus.21 In fact Asians, particularly South 
Asian have the highest burden of diabetes mellitus.30,31 Other studies have reported 
that among the ethnic or racial groups, Blacks with ACS have the highest rates of 
acute cardiovascular mortality, whereas Asians have the lowest. Likewise, other 
adverse cardiovascular events seem to be higher in Blacks and lower in Asians. 
Overall Blacks have the lowest incidence of coronary artery disease (CAD).21 In 
contrast, Asians particularly South Asians have a much higher incidence of CAD.32 
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2.6 The impact of socioeconomic status on ACS 
 
Differences in socioeconomic status have been consistently linked with variations in 
cardiovascular disease and mortality rates.33-35 Despite a strong and consistent 
relationship between socioeconomic status and cardiovascular health, much still 
need to be understood about the ways in which socioeconomic status influences or 
affects health.36 Individuals with low income are more likely to smoke, to have 
diabetes mellitus or hypertension. This may result in accelerated atherosclerosis and 
subsequent higher mortality rates. A study conducted in Ontario reported 8.0% 
obesity, 33.0% diabetes mellitus, 49.5% hypertension and 32.3% smokers among 
low-income patients whereas in high-income patients the same study reported 3.1% 
obesity, 19.4% diabetes, 35.9% hypertension, and 27% smokers.33 
 
Wealth-health gradient is observed worldwide, including in countries where health 
care is funded by the state. The wealth–health gradient does not dependent on the 
socioeconomic indicator used and persists even after such cardiovascular events as  
myocardial infarction.33 The causes of these gradients are debatable37-39 and  need 
clarification.36 Outcome-income gradients have been found to persist even after 
adjustment for traditional cardiac risk factors and cardiovascular events.33 These low 
income or education related effects are likely due to increased psychosocial 
stressors, lack of lifestyle change after ACS and limited access to medical care.40,41 
 
2.7 The impact of alcohol on ACS 
 
There is an association between mild regular alcohol consumption and a decreased 
risk for developing coronary heart disease whereas heavy alcohol intake and binge 
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drinking are associated with increased cardiovascular mortality.42 Mortality and 
morbidity related to ACS is less in non-alcohol related presentations than in patients 
presenting with alcohol intoxication.43 Heavy binge drinking may also be associated 
with myocardial infarction, but the underlying mechanisms are unclear.42 Acute 
myocardial infarction in young individuals has been described after heavy alcohol 
intake.43 
  
Acute ethanol intoxication may precipitate ACS via several mechanisms. Alcohol has 
been reported to induce coronary spasm by unknown mechanisms as long as 9 
hours after drinking, even after plasma ethanol has been cleared. Low levels of 
prostaglandin F1-alpha and cyclic guanosine monophosphate are incriminated in the 
mechanism of coronary spasm induced by alcohol ingestion.42 In addition to 
coronary spam, several other mechanisms have been proposed by which alcohol 
may trigger ACS.44 These include transient enhancement of thromboxane-mediated 
platelet activation, induction of changes in the normal circadian periodicity of the 
haemostatic system and inhibition of fibrinolysis.45      
 
Heavy alcohol intake is associated with an increased risk of hypertension,46 which in 
turn is a major risk factor for coronary heart disease.46,47 In comparison to those that 
abstain from alcohol, light to moderate alcohol intake is associated with a lower risk 
of coronary heart disease.48,49 This is likely due to increased levels of high-density 
lipoprotein (HDL), decreased fibrinogen and increased insulin sensitivity in 
individuals that consume light to moderate amounts of alcohol.50 
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2.8 Common risk factors for ACS 
 
Risk factors associated with ACS can be divided into modifiable and non-modifiable 
risk factors.8 Modifiable risk factors include obesity, smoking, use of cocaine, 
abnormal lipid profile, hypertension, diabetes mellitus, sedentary lifestyle, chronic 
kidney disease,2, 8, 51 HIV / AIDS and antiretroviral therapy (ART).13 Hypertension is a 
major public health problem, accounting for nearly 13% of all deaths across the 
world and 17% of all deaths in developed countries.46  In a study, 41%52 of patients 
with ACS were smokers, whilst another study reported an incidence of 63%.53 In 
another study, 25% of patients with ACS were obese.54  Other studies reported the 
incidence of dyslipidaemia in patients with ACS as16%,55 30.5%54 and 59%.56  
Hypertension was reported in 34%,55 50%,52 50.8%54 and 75%56 of patients with 
ACS in different studies.  The incidence of diabetes mellitus was reported as 16%,55 
23.9%,57 24.3%,58 and 38%54 in various studies.  
 
Non-modifiable risk factors include family history of coronary artery disease (first 
degree relative: male ˂ 55 years, female ˂ 65 years), older age, sex (male more than 
female), prior manifestation of CAD (previous MI, PCI (percutaneous coronary 
intervention), CABG surgery, atherosclerosis in non-coronary territories (stroke),51  
race (higher in people of Indian descent).59, 60  In a study, 15.6% of patients had 
history of prior CABG surgery, 9.0% had a history of prior of stroke, 15.2% had prior 
PCI and 29.7% had prior MI.61 Another study reported history of PCI, CABG, stroke 
and MI in 26.83% ,23.06%, 11.76% and 42.89% respectively in patients that 
presented with ACS.53  
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The risk for cardiovascular disease (CVD) among individuals with diabetes mellitus is 
2 to 3 times higher compared to non-diabetics. Obesity and overweight are reported 
as independent risk factor for CVD, and are associated with higher rates of 
cardiovascular related deaths. Smokers have a 70% higher risk for coronary artery 
disease (CAD) compared to non-smokers. This risk is proportionate to the pack year 
history of smoking.62 A greater number of risk factors for CAD is associated with 
higher morbidity and mortality.2,63  
 
Regular physical activity reduces the risk for CAD as opposed to a sedentary 
lifestyle. Several other measures are known to reduce the risk for CVD. These 
include control of hypercholesterolaemia, obesity and hypertension.62 
The INTERHEART study examined the importance of risk factors for CAD.64 The five 
modifiable risk factors found to be predictive of CAD were current smoking, raised 
apoprotein B – apoprotein A1 ratio, diabetes, hypertension and psychosocial stress.
64 
The INTERHEART study also demonstrated that these risk factors are consistent 
across a wide range of cultural, ethnic and geographic regions around the globe.65  
 
2.9 Specific risk factors 
 
2.9.1 HIV 
South Africa is the Sub-Saharan country housing one of the largest populations living 
with HIV worldwide13, with 6.4 million HIV infected individuals reported in the 2013 
UNAIDS report.14 The South African department of health estimated that 18.3% of 
young adults between the ages of 15 and 49 years were living with HIV in 2006,66 
with more than half of all HIV positive patients residing in the KwaZulu-Natal and 
Gauteng provinces.67 The HIV prevalence among Black South Africans is the highest 
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and is estimated as 12.9%. White and Indian South Africans have an estimated HIV 
prevalence of 6.2% and 1.6% respectively.68   
 
Post-mortem studies conducted in HIV positive patients from high-income countries 
have demonstrated high rates of atherosclerosis related CAD compared to aged-
matched HIV negative patients.69 HIV infection on its own can predispose to 
premature atherosclerosis by several mechanisms including endothelial dysfunction, 
a heightened  pro-inflammatory state and dyslipidaemia such as elevated triglyceride 
levels and low levels of high density lipoprotein (HDL) cholesterol.18  
 
In addition to premature atherosclerosis, HIV is associated with a higher risk of 
thrombosis, as a result of various abnormalities of the coagulation and fibrinolytic 
systems. Furthermore, studies have reported a strong link between highly active 
antiretroviral therapy (HAART) and premature coronary artery disease (CAD).18 
Protease inhibitors in particular have been associated with endothelial dysfunction, a 
prothrombotic state, insulin resistance and dyslipidaemia.70 Prolonged exposure to 
protease inhibitor has been associated with an increased risk for developing ACS. 
Even before the advent of protease inhibitor for the treatment of HIV/AIDS, post-
mortem studies have reported premature CAD in HIV infected patients.18 Therefore, 
both HIV and antiretroviral therapy (ART) play a role in the development of CAD and 
ACS. Becker and colleagues in a study conducted in Soweto, South Africa found that 
antiretroviral therapy naive HIV positive patients with ACS were younger and had 
fewer traditional risk factors than HIV negative patients with ACS. HIV positive 
patients also had less atherosclerotic and a higher thrombotic burden. This suggests 
that a prothrombotic state may play a role in the pathogenesis of ACS in patients 
with HIV.71 
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Triant et al. has reported increased rates of AMI and cardiovascular risk factors in 
patients with HIV. In this study, the HIV cohort had a higher prevalence of 
hypertension (21.2% vs. 15.9%), diabetes (11.5% vs. 6.6%), and dyslipidaemia 
(23.3% vs. 17.6%) than the non-HIV cohort. The study also reported AMI rates of 
11.13 per 1000 patient-years for HIV and 6.98 per 1000 patient-years for non-HIV.72 
 
2.9.2 Renal Failure 
Renal failure is recognised as a well-defined risk factor of cardiovascular disease.73 
There is an increased morbidity and mortality associated with percutaneous coronary 
intervention (PCI) in patients with chronic kidney disease (CKD).74 Patients with CKD 
requiring haemodialysis are also at increased risk of developing cardiac ischaemia 
as a result of the induced hypercoagulable state from membrane and haemodialysis 
circuit contact, especially if subtherapeutic doses of anticoagulation are used.73 
 
Chronic kidney disease is considered both a coronary risk equivalent and a risk for 
progression of cardiovascular disease.75 The increase in cardiovascular mortality in 
chronic kidney disease patients may be explained by pump failure and arrhythmias. 
The rate of myocardial infarction (MI) is higher in patients with chronic kidney 
disease when compared to the general population.76 The pathophysiology includes 
decreased myocardial capillary density, cardiomyocyte dysfunction, increased left 
ventricular mass, impaired ion reutilization, anaemia, erythropoietin deficiency, 
abnormal calcium–phosphate homeostasis with phosphate retention, 
hyperparathyroidism, inflammation, hypervoleamia, and hyperhomocysteinemia.75 All 
of these disruptions may lead to myocardial dysfunction and fibrosis.77 Therefore, 
chronic kidney disease patients in the setting of ACS are more prone to develop 
arrhythmia, left ventricular dysfunction and subsequent death than the general 
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population.76 The risk of cardiovascular death in patients with moderate chronic 
kidney disease is similar to risk of cardiovascular death in patients with diabetes 
mellitus or previous myocardial infarction.75 The incidence of renal failure in patients 
with ACS has been reported as 15%54 and 17.4%61 in two studies. 
 
Acute coronary syndrome (ACS) patients presenting with chronic kidney disease 
demonstrate more extensive coronary artery disease and have higher risk for heart 
failure, re-infarction and death than ACS patients without coronary artery disease. 
They are also more likely to have delayed or atypical presentations. As a result they 
are less likely to receive appropriate therapy than are patients without renal 
impairment.75   
 
Recent studies have found that patients with reduced estimated glomerular filtration 
rate (eGFR) have a high prevalence of coronary artery disease, myocardial 
infarction, and cardiovascular death than the general population. They also have a 
poorer outcome post ACS than those without renal impairment.78    
 
In South Africa, hypertension has been attributed as the cause of chronic kidney 
disease in 21% of patients on renal replacement therapy. Hypertension was also 
reported as the commonest cause of end-stage renal disease in 34.6% of black 
South African, 20.9% of people of mixed ancestry, 13.8% of Indians, and 4.3% of 
Whites.79  
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2.10 Typical presenting symptoms 
 
Although there is a consensus description about what represents typical chest pain, 
the equivalent definition for atypical chest pain remains less clear. The first 
description of typical ischemic chest pain was provided by Heberven who defined it 
as a painful sensation in the breast accompanied by a strangling sensation, anxiety, 
and occasional radiation of pain to the left arm.6 Currently, typical chest pain is 
described as pressure, tightness, or heaviness; it may radiate to the neck, jaw, 
shoulders, back, or one or both arms.4, 51 It may also be accompanied by other 
symptoms such as shortness of breath, sweating, nausea, vomiting, dizziness,7 
abdominal pain, diaphoresis, and syncope.51 In a study, 70.8% of patients presented 
with typical chest pain.80 Another study reported 83% of patients with typical chest 
pain.54 
 
2.11 Atypical presenting symptoms and missed diagnosis 
 
Atypical chest pain and presentation of ACS is another confounder that may 
increase the incidence of missed or delayed diagnosis. Emergency Physicians (EP) 
are faced with this problem which is further complicated by cultural differences, 
ethnic differences and language barriers in various patient populations. Clinicians 
therefore must have a high index of suspicion for the work up of ACS with suspicious 
presentations.2,4 
 
Atypical chest pain includes signs and symptoms that do not fit the classically 
described complaints associated with myocardial ischaemia. The description of chest 
pain thought to be atypical may include sharp or stabbing pain, pain reproduced by 
 
 
18 
palpation or position change, pleuritic chest pain, burning pain or indigestion. The 
pain may also be described as indigestion or heartburn with associated nausea and 
or vomiting.4 In the absence of the pain, other symptoms termed non-pain 
equivalents6 may include shortness of breath, weakness, dizziness, light-
headedness, loss of consciousness,81 nausea, and diaphoresis.4 ACS atypical 
presentations are commonly observed in women, older patients (˃ 75 years), and 
patients with diabetes7, chronic renal failure, or dementia.82,83  Several studies have 
reported the incidence of atypical chest pain as between 4.7% and 33%.3,54,84-86 
 
As described above, the distinction between typical and atypical chest pain is 
blurred,6 especially given that patients and doctors may communicate in languages 
that are not their first language, and many nuances of description may be lost in 
translation. 
 
During the initial contact with a patient presenting with chest pain, the goals of the 
emergency physician are to determine the likelihood of ACS or non-ACS, exclude 
other life-threatening causes of chest pain6 and appropriate disposition (admit, 
discharge with appropriate counselling, etc.) of the patients. The greatest pitfall 
during assessment of ACS patients in the absence of chest pain is the failure to 
consider the diagnosis of cardiac ischaemia.4  
 
The rates of missed diagnosis of ACS vary from 2% to 4% in centres in the USA.4 
Factors associated with inadvertent discharge of patients with missed cardiac 
ischaemia include younger age, atypical symptoms, women, non-white race, 
physician inexperience, failure to detect ischaemia on initial ECG, failure to obtain an 
ECG.87,88 Missed and delayed diagnosis of ACS is associated with high morbidity 
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and mortality.89 Patients discharged from the ED with a missed diagnosis of ACS 
have been reported to have mortality rates ranging between 10% and 25%.4 
 
In an attempt to identify patients with low-risk chest pain, several studies have 
proposed different predictive models, including the Thrombolysis In Myocardial 
Infarction (TIMI) risk score, Sanchis rule, and the Vancouver rule. Despite the 
development of multiple risk stratification systems, none of these predictive models 
allows one to safely discharge patients home. It is important for a physician to 
understand that many early risk stratification models were derived using high risk 
patients and therefore, do not equate low risk presentations as ʺno risk.ʺ4 
 
2.12 Complications of ACS 
 
Complications associated with ACS comprise haemodynamic disturbances and 
mechanical complications. The later includes mitral valve regurgitation, cardiac 
rupture, ventricular septal rupture, right ventricular infarction, pericarditis, left 
ventricular aneurysm, left ventricular thrombus,90 and post-infarction infarct 
extension.91  Haemodynamic disturbances include arrhythmias such as ventricular 
tachycardia (VT) and ventricular fibrillation (VF), conduction disturbances and heart 
failure. Heart failure may be accompanied by hypotension, pulmonary congestion, 
low output status and cardiogenic shock. 90 Cardiac failure rates of 5.8%,92 14%,93 
16%54 and 26%56 have been reported in different studies. Studies have reported 
cardiogenic shock rates of 4.1%,58 4.5%,54 and 7.3%.61 
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2.13 ECG findings 
 
As early as 1917, myocardial infarction related changes were identified on ECG, 
allowing the ante-mortem recognition of coronary occlusion for the first time. A 
decade later, ECG became an integrated part of the work up of a patient that 
presented with chest discomfort.94 The characteristics of common ECG abnormalities 
in various locations are summarised in table 1.95 
 
The ECG continues to be the most important, cost-effective and immediately 
available initial test in identifying coronary occlusion and in the decision-making 
process for emergency reperfusion therapy as it allows categorising ACS as STEMI 
or NSTEMI / UA. However, the accuracy of ECG remains less optimal.96 The 
sensitivity and specificity of the ECG depend on the number and extent of 
abnormalities.2,95  
 
Alternative diagnosis or pseudo-infarction patterns in patients presenting with ST-
segment elevation include early repolarization, pericarditis, left bundle branch block 
(LBBB), left ventricular aneurysm morphology, brugada syndrome and left ventricular 
hypertrophy (LVH).97  
 
Subendothelial ischaemia can lead to ST-segment depression and T-wave inversion. 
Among patients with ST-segment depression, approximately 25% eventually develop 
STEMI and the remaining 75% may demonstrate NSTEMI. Q wave ˃ 0.04 second 
and at least one quarter of the height of the corresponding R wave is termed a 
significant Q wave. Small Q waves, referred to as septal Q waves, may be normal 
when present in leads II, III, and aVF and leads I and aVL. Classically, ECG changes 
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occur in STEMI, but a completely normal ECG may also be present in a patient with 
myocardial ischaemia.95 A new or presumably new LBBB is considered equivalent to 
ST-segment elevation.2,98 But this principle has been questioned as a study has 
demonstrated that less than half of patients with presumably new LBBB actually had 
AMI.98 
 
Table 1: Summary of ECG findings for the diagnosis of acute coronary 
syndrome 
Reprinted with permission from Achar SA, Kundu S, Norcross WA. Diagnosis of 
acute coronary syndrome. Am Fam Physician 2005(1); 72:119-26.95 Copyright © 
2005 by the American Academy of Family Physicians.  
 
The diagnosis of chest pain secondary to ACS remains challenging and problematic, 
particularly in patients initially thought to be at low risk for developing cardiac 
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ischaemia.4 Moreover, diagnostic and therapeutic challenges arise again particularly 
when the ECG is normal or nearly normal, or when it is abnormal at the base line 
because of underlying conditions.51 The 12-lead ECG may be non-diagnostic in 
patients with acute MI secondary to an occlusion of the left circumflex coronary 
artery or right coronary artery. Indeed, 26% to 60% of patients may have a normal 
ECG on presentation.2 A 15 lead ECG (includes V4R, V8 and V9) may diagnose 
right ventricular and posterior left ventricular infarction and therefore increases the 
diagnostic sensitivity of the ECG. Ideally, within 10 minutes upon arrival at the ED, 
providers should obtain a 15-lead ECG.51  
 
In the absence of left ventricular hypertrophy or left bundle branch block, ST-
segment elevation in acute myocardial infarction is defined as ≥ 1 mm elevation 
measured at the J point in any 2 contiguous leads except in leads V2 and V3. In 
these two leads (V2/V3) the ST-segment elevation should be ≥ 2.5 mm in men under 
the age of 40 years, ≥ 2mm in men over the age of 40 years, or ≥ 1.5 mm in 
women.90 
 
The ACCESS study and a study conducted by Lemos et al in 41 countries have 
reported the incidence of NSTEMI as 59%57 and 60% 52 respectively. The above two 
studies also reported the incidence of STEMI as 41%57 and 40% 52 respectively. 
Other studies reported an incidence of STEMI of 15% and 27%.53, 99 The PURSUIT 
study reported 39.1% of patients with ST-segment depression, 16.4% with ST-
segment elevation and 49.1% with T wave inversion in the American cohort, and 
56%, 12.7% and 51.4% respectively in the non-American cohort.100 Other studies 
reported 2%,98 2.4%101 and 6%102 incidence of LBBB among ACS patients. 
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2.14 Cardiac biomarkers 
 
Cardiac biomarkers play an important role in the diagnosis of acute coronary 
syndrome. Characteristic of the most used serum cardiac biomarkers and their 
release kinetics are presented respectively in table 2 and figure 1. The challenge in 
diagnosing ACS is further escalated, given the fact that cardiac biomarkers (troponin 
I and T (Tn I and Tn T) and creatine kinase isoenzyme (CK-MB)) are insensitive 
during the first 4 to 6 hours,7 contributing to under recognition of atypical ACS and 
subsequent poor outcomes.103,104   
 
Table 2: Characteristics of cardiac biomarkers for the diagnosis of acute 
myocardial infarction. 
Reprinted with permission from Achar SA, Kundu S, Norcross WA. Diagnosis of 
acute coronary syndrome. Am Fam Physician 2005(1); 72:119-26.95 Copyright © 
2005 by the American Academy of Family Physicians.  
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Figure 1: Time course of release of serum cardiac markers after acute 
myocardial infarction.  
Reprinted with permission from Panteghini M. Acute coronary syndrome: 
biochemical strategies in the troponin era. Chest 2002; 122(4):1428-35.89 Copyright 
© 2002 by the American College of Chest Physicians. 
   
2.15 Management of ACS 
 
The goals of treatment for ACS include identification of patients with ST elevation MI 
for early reperfusion therapy, relief of chest discomfort, treatment of life-threatening 
complications such as VF, VT, unstable tachyarrhythmia’s and prevention of major 
adverse cardiac events (MACE).105 The treatment strategy for ACS patients is based 
on duration and persistence of symptoms, the initial ECG, cardiac history and 
findings on physical examination.91 The American Heart Association and the 
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European Society of Cardiology have both recommended guidelines for the 
management of ACS.1,2,51,90,105 
 
Initial therapy in the management of patients with ACS includes administration of 
oxygen to maintain saturation above 94%, aspirin, nitroglycerine and morphine if 
pain is not relieved by nitroglycerine. Acute relief of pain reduces myocardial oxygen 
demand and attenuates the hyperactive catecholamine state.105 In addition to pain 
relief, nitroglycerine also acts as a vasodilator.106 Oxygen administration has been 
shown to reduce ST-segment elevation in anterior infarction.107, 108 The second 
international study of infarct survival (ISIS-2) has shown the efficacy of aspirin in 
reducing death from MI.106 Aspirin has additional benefits when given with 
thrombolytic agents109 and reduces nonfatal AMI by 30% and vascular death by 17% 
in high-risk patients.110  
 
The management of STEMI relies on the “open artery theory” which stipulates that a 
prompt and complete restoration of blood flow limits infarct size, preserves left 
ventricular (LV) function and improves survival rates.106 Pharmacological therapy 
(fibrinolysis) and mechanical means (PCI) are the two methods currently available 
for restoring coronary perfusion.106,111 
 
The following is a summary of the recent European Society of Cardiology (ESC) 
guidelines regarding the principles of early reperfusion therapy:90  
 Fibrinolytic therapy is recommended within 12 hours of symptom onset in 
STEMI patients without contraindications to fibrinolytic therapy, if an 
experienced team cannot perform primary PCI within 120 min of first medical 
contact. 
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 In STEMI patients presenting early (<2 h after symptom onset) with a large 
infarct and low bleeding risk, fibrinolysis should be considered if time from first 
medical contact to balloon inflation is >90 min. 
 If possible, fibrinolysis should start in the prehospital setting.  
 A fibrin-specific agent (tenecteplase, alteplase, reteplase) is recommended 
over non-fibrin specific agents.  
 Oral or intravenous aspirin must be administered.  
 Clopidogrel is indicated in addition to aspirin.  
 Transfer to a PCI-capable centre following fibrinolysis is indicated in all 
patients after fibrinolysis.  
 Rescue PCI is indicated immediately when fibrinolysis has failed (<50% ST-
segment resolution at 60 min).  
 Emergency PCI is indicated in the case of recurrent ischaemia or evidence of 
re-occlusion after initial successful fibrinolysis. 
 Primary PCI is indicated in acute severe heart failure / cardiogenic shock 
patients, unless the expected PCI related delay is excessive and the patient 
presents early after symptom onset.  
 Angiography with a view to revascularization (of the infarct-related artery) is 
indicated after successful fibrinolysis.  
 Optimal timing of angiography for stable patients after successful fibrinolysis 
is 3–24 hours. 
 
Fibrinolytic therapy is contraindicated in patients with NSTEMI / UA. According to the 
ESC guidelines for patients without persistent STEMI, high risk NSTEMI / UA should 
undergo coronary angiography within 24 hours of symptom onset, whereas low risk 
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NSTEMI / UA should undergo coronary angiography within 72 hours of symptom 
onset.51 
 
Table 3: ESC recommendations for reperfusion therapy 
 
Reprinted and adapted with permission from Steg PG, James SK, Atar D, Badano 
LP, Blomstrom-Lundqvist C, et al. ESC Guidelines for the management of acute 
myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 
2012; 33(20): 2569-2619.90 Copyright © 2012 European Society of Cardiology.   
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2.16 Patient outcomes after ACS 
 
Indicators that can be used to assess patient outcomes after ACS include time to 
clinical stability, length of hospital stay, and mortality rate (in-hospital mortality rate). 
A median length of hospital stay post ACS of 8 days was reported in a Swiss study. 
This study also showed that a longer length of hospital was associated with a higher 
mortality.112 The PURSUIT study reported mean length of hospital stay post ACS of 8 
days and 10 days in the American and non-American cohorts respectively.100 The 
first and second SYMPHONY studies have reported median time to clinical stability 
of 3.6 days and 3.7 days respectively.113 The in-hospital mortality rate at a study 
conducted at the University of Michigan has been reported as 6.9%61 whilst another 
North American study reported an in-hospital mortality rate of 6.3%.114 Other studies 
reported in-hospital mortality rates between 3.27% and 5.3%.54,58,93 
 
 
 
 
29 
CHAPTER 3 
METHODOLOGY 
 
3.1 Ethical considerations 
 
Permission to conduct this study was granted by the Ladysmith Provincial Hospital 
management, and by the KwaZulu-Natal Health Research Committee. Ethics 
clearance was obtained from the Human Research Ethics Committee (medical) 
(HREC (medical)) of the University of the Witwatersrand (clearance certificate M 
120801 – Appendix 1, p 82). In accordance with the principles of patient 
confidentiality, patient-identifying information was not recorded in the data collection 
sheet and a unique patient identification number (PIN) was assigned to all patients 
studied, starting from 001. PIN was known only to the researcher allowing for patient 
confidentiality to be respected at all times. Scanned medical records were stored in a 
password-protected folder in a password-protected computer only accessible to the 
researcher. Patient identifying information was blocked out and replaced with a 
unique PIN number for each patient prior to scanning. This folder will be deleted at 
the end of the study. 
 
3.2 Design of the study 
 
This is a cross-sectional, hospital-based, descriptive, retrospective audit of medical 
records. 
 
 
 
 
 
30 
3.3 Site of the study 
 
The study was conducted at the Ladysmith Provincial Hospital in KwaZulu-Natal. All 
of the patients included in the study initially presented to the ED. These patients 
were further managed either in the adult ICU, high care ward or medical ward. 
  
3.4 The study population 
 
The study population consisted of adult patients that presented to the Ladysmith 
Provincial Hospital ED and had a final hospital discharge diagnosis of ACS.   
 
3.5 Inclusion criteria 
 
 All patients with a final diagnosis of STEMI. 
 All patients with a final diagnosis of NSTEMI. 
 All patients with a final diagnosis of UA.  
 
3.6 Exclusion criteria 
 
 Patients diagnosed as stable angina.  
 Patients with an initial diagnosis of ACS but later reviewed to another 
diagnosis (e.g. pulmonary embolism, acute pericarditis, dissecting aortic 
aneurysm).  
 Patients whose medical records could not be accessed.  
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3.7 Data collection 
 
 The researcher, who had spent about four hours informally researching 
methodologies regarding retrospective data collection from medical records, 
collected all available data. The researcher did not attend any formal certified 
training course regarding retrospective data collection from medical records. 
 The researcher was not blinded to the study aims and objectives. 
 The study supervisor was frequently consulted during the period of data 
abstraction  
 Data collection was initiated on 1st June 2013. 
 Eligible patients, meeting study criteria and who presented to the Ladysmith 
Provincial Hospital ED before 1st June 2013 at 00:00 were included in the 
study. 
 The researcher reviewed Ladysmith hospital ED registers.  
 The researcher also reviewed intensive care unit, high care ward and the 
medical ward registers to identify patients with ACS that were misdiagnosed 
in the ED and later diagnosed in these wards.  
 All the above registers had documented as standard hospital protocol, the 
final patient diagnoses before transfer out of the ED or before discharge from 
the ICU, high care ward and medical ward. 
 138 patients were required as per sample size calculation (see below). 
 A sample size of 160 patients was agreed upon to account for a possible 15% 
of medical records with incomplete data entry. 
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 In anticipation that approximately 30% of patient records may not be available 
due to missing files, 210 potential patient names and patient file number, with 
diagnosis that met study criteria were selected from the above registers. 
 Medical records of these patients were requested and obtained from the 
hospital records department.  
 The respective wards and available doctors were contacted in an attempt to 
find medical records that could not be found at the hospital records 
department. 
 Patients whose medical records could still not be accessible were excluded 
from the study. 
 For ease of later reference, all medical records that met study criteria were 
scanned and stored in a password-protected folder in a password-protected 
computer only accessible to the researcher. Patient identifying information 
was blocked out and replaced with a unique PIN number for each patient prior 
to scanning. This folder will be deleted at the end of the study. 
 Data from available medical records meeting the study criteria were 
abstracted and entered into a specifically designed data collection sheet 
(Appendix 2, p 83 - 85).   
 Captured data included age, sex, race, duration of hospital stay (calculated 
from date of admission to the date of discharge), risk factors for ACS, 
presenting complaints at the ED, vital signs (BP, HR, RR, GCS), presenting 
ECG, initial laboratory data (CK-MB, troponin T, haemoglobin, urea, creatinine 
and total cholesterol), initial management, reperfusion therapy, and patient 
outcomes (step-down, step-up, time to clinical stability and death). 
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 The set of vital signs recorded on presentation before any therapeutic 
intervention was performed, were recorded in the data collection sheet as the 
vital signs on presentation. If more than one set of vital signs was recorded on 
initial presentation, the set of results that was closest to the normal range was 
used. Any set of vital signs reported as spurious by the attending clinician or 
regarded as spurious by the researcher were excluded.   
 Any other conflicting data entries (which were few) was assessed by the 
researcher, who taking the rest of the patient assessment and also the 
considerations of the most qualified attending clinician into account, decided 
as to which data to enter in to the data collection sheet. 
 Missing data: Negative findings were not recorded in the archived medical 
records for most of the following subsets of categorical data: presenting 
features of study patients (chest pain, associated symptoms, radiation of pain, 
etc….), risk factors for ACS of study patients, socio-economic and behavioural 
characteristics of study patients, management of study patients, outcomes of 
study patients, etc…. Where these negative findings were not recorded in the 
medical records, they were regarded as negative findings by the data 
abstractor (researcher).   
 To assess for inter-rater reliability, data from a sample of 25 randomly 
selected medical records was re-abstracted by an independent person with 
previous experience in data abstraction from medical records. He was blinded 
to the study methodology and to the information obtained by the researcher.  
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3.8 Sample size estimation   
 
Acute coronary syndrome (ACS) accounts for about 10% of patients presenting to 
the Ladysmith Provincial Hospital ED per annum (hospital registry, 2000 - 2012). 
Assuming an ACS prevalence of 10%, a 5% margin of error, and a 95% confidence 
level, the minimum sample size required was calculated as 138 using the online 
Raosoft sample size calculator.  One hundred and sixty subjects were enrolled in the 
study to account for a possible 15% of medical records with incomplete data entry. 
                
3.9 Data analysis 
  
All data recorded in the data collection sheets were entered into an electronic data 
spread sheet for analysis (Microsoft® Excel®). STATA ® version12 software was 
used to perform all statistical analyses. Categorical (gender, race, risk factors, 
presenting features, death) and continuous (age, duration of hospital stay, vital 
signs, laboratory data, time to clinical stability) data have been described in the next 
chapter. Means, standard deviations, medians, ranges, flow diagrams, tables, 
histograms, bar charts and pie charts have been used where appropriate. 
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CHAPTER 4 
RESULTS 
 
4.1 Inter-rater reliability 
 
Eight randomly selected variables from the data collection sheets were assessed. 
These selected data from a sample of 25 randomly selected medical records was re-
abstracted by an independent person with previous experience in data abstraction 
from medical records. He was blinded to the information obtained by the researcher. 
The average intraclass correlation coefficient was 0.93 (95% CI, 0.79 – 0.98).  
 
4.2 Final study sample 
 
One hundred and ninety seven consecutive patients from the sample of 210 names 
selected from the four registers (ED, ICU, high care and medical ward) were required 
to make up the eligible 160 patients that met study criteria. A total of 37 patients 
(18.8%) were excluded from the study. Out of this number, 29 patients (14.7%) had 
no accessible medical records. Five patients (2.5%) were initially assessed as ACS 
in the ED, but had their final discharge diagnosis reviewed to stable angina. Another 
three patients (1.5%) were initially assessed as ACS in the ED, but had their final 
discharge diagnoses reviewed to pericarditis. Therefore, assuming that the 29 
patients without available medical records would have had a final hospital discharge 
diagnosis of ACS, the false positive diagnosis rate for ACS at the Ladysmith 
Provincial Hospital ED over the study period was 4.1% (8/197). 
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Figure 2: Flow diagram describing the process in achieving the final study 
sample  
 
4.3 General description of the final sample 
 
A total of 160 patients were included in the study. This comprised of 103 Asians (66 
males, 37 females), 36 Blacks (15 males, 21 females) and 21 Whites (9 males, 12 
females). The overall sex distribution comprised 90 males and 70 females. A male to 
female ratio of 1.3: 1.  
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4.4 Frequency of patients presenting with ACS to the ED 
 
Assuming that the 29 patients for whom no medical records could be found had a 
final hospital discharge diagnosis of ACS, a total of 189 patients presented with ACS 
to the Ladysmith Provincial Hospital ED over the study period. These 189 patients 
presented from 1 November 2009 to 31 May 2013, a period of 43 months. This 
represents a frequency of approximately 53 patients per annum.  
 
From the 160 patients with available hospital records, 3 patients (1.9 %) were not 
initially diagnosed with ACS in the ED (false negative diagnosis rate). Two patients 
were later diagnosed with UA in the medical ward and the other patient was 
diagnosed with NSTEMI in the ICU. All three patients were male, had no chest pain 
on presentation and were aged 57, 69 and 77 years respectively. Two patients had 
concurrent pneumonia and the third patient was misdiagnosed as acute pericarditis. 
However all three patients were eventually diagnosed with ACS within 10 hours of 
presentation to hospital and all of them survived and had good short-term outcomes. 
 
4.5 Clinical stability of patients on presentation 
 
4.5.1 Summary of vital signs of study group on presentation to the ED 
The results for baseline vital signs of study patients (systolic blood pressure, diastolic 
blood pressure, heart rate and respiratory rate) are summarised in Table 4.  
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Table 4: Summary of results for baseline vital signs of study patients 
SD=Standard Deviation 
 
4.5.2 Systolic Blood Pressure (SBP) 
 
Figure 3: Frequency histogram for SBP of study patients  
  
The frequency histogram for systolic blood pressure of study patients is shown in 
Figure 3. The median SBP for the study population was 122 mmHg and ranged 
between 66 and 230 mmHg. The mean (SD) was 132.9 (27.4) mmHg. The majority 
of the study patients had a SBP between 120-139 mmHg (43/160, 26.9%). Two 
study patients had a SBP of > 220 mmHg (2/160, 1.3%).  
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4.5.3 Diastolic Blood Pressure (DBP) 
The frequency histogram for diastolic blood pressure of study patients is shown in 
Figure 4. The median DBP for the study population was 83.5 mmHg and ranged 
between 43 and 140 mmHg. The mean (SD) was 84.2 (16.9) mmHg. The majority of 
the study patients had a DBP between 60-99 mmHg (121/160, 75.6%). Two study 
patients had a DBP of > 120 mmHg (2/160, 1.3%). 
 
Figure 4: Frequency histogram for DBP of study patients  
 
4.5.4 Heart Rate (HR) 
The median heart rate for the study population was 85 beats per minute and ranged 
between 38 and 147 beats per minute. The mean (SD) was 87.3 (19.2) beats per 
minute. The majority of the study patients had a heart rate between 70-89 beats per 
minute (75/160, 46.9%).  
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4.5.5 Respiratory Rate (RR) 
The median respiratory rate for the study population was 20 breaths per minute and 
ranged between 12 and 40 breaths per minute. The mean (SD) was 21.3 (4.2) 
breaths per minute. The majority of the study patients had respiratory rates between 
20 to 24 breaths per minute (114/160, 71.3%).  
 
4.5.6 Glasgow coma scale (GCS) 
All study patients had only a single GCS score recorded in the ED presentation form. 
Two study patients presented with confusion. The GCS score was 13 for both of 
these patients (table 5).  
 
Table 5: Frequency distribution table for GCS score of study patients  
GCS score N % 
13 2 1.3 
15 158 98.7 
Total 160 100 
 
 
4.6 Presenting features of study patients  
 
4.6.1 Chest pain 
Approximately three quarters (119/160, 74.4%) of the study patients had typical 
chest pain, 16.3% (26/160) had atypical chest pain, and the remaining 9.4% (15/160) 
had no chest pain, as shown in Figure 5. 
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Figure 5: Frequency bar chart describing chest pain of study patients 
 
4.6.2 Presenting symptoms of patients with no chest pain 
From a total of 15 study patients who reported no chest pain, their presenting 
symptoms were as follows. The majority (10/15, 66.7%) had dyspnoea only and the 
remaining five had a combination of dyspnoea, fatigue, fainting, dizziness, sweating, 
nausea, and vomiting, as shown in Table 6.   
 
Table 6: Frequency distribution table for presenting symptoms of study 
patients with no chest pain 
 N % 
Dyspnoea only 10 66.7 
dyspnoea, fatigue 2 13.3 
fainting, dizziness, sweating, nausea 1 6.7 
vomiting, fatigue 2 13.3 
Total 15 100 
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4.6.3 Associated symptoms of all study patients 
 
Figure 6: Frequency bar chart describing associated symptoms of study 
patients 
 
The majority of the study patients (31/160, 19.5%) had dyspnoea, others had no 
associated symptoms (20/160, 12.6%), nausea (15/160, 9.4%), sweating (15/160, 
9.4%), nausea and vomiting (12/160, 7.6%) and dizziness (10/160, 6.3%). The rest 
of the study patients had combinations of some of the following: dyspnoea, 
dizziness, malaise, nausea, vomiting, abdominal pain, body weakness, numbness, 
palpitation, sweating, and fainting. Figure 6 show the frequency distribution of 
associated symptoms for all study patients. 
 
4.6.4 Radiation of pain 
The majority of the study patients had radiation of pain to the left arm (50/160, 
31.3%), left shoulder (18/160, 11.3%), and the back (9/160, 5.6%) only. Some had 
no radiation of pain (14/160, 8.8%). The remaining study patients had radiation of 
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pain to a combination of the back, left arm, left shoulder, jaw, neck and left side of 
the body. This frequency distribution is shown in Figure 7. 
 
Figure 7: Frequency bar chart describing radiation of pain of study patients  
 
4.6.5 Cardiogenic shock 
Only six patients in the study group (6/160, 3.8%) developed cardiogenic shock.  
 
4.6.6 Cardiac failure 
Almost twenty per cent of the study patients (31/160, 19,4%) developed cardiac 
failure as a consequence of ACS. None of the study patients had echocardiography 
performed at Ladysmith Provincial Hospital due to unavailability. 
 
4.6.7 ECG findings 
Sixty-two patients (38.8%) presented with ST segment elevation and 4 patients  
(2.5%) presented with presumably new LBBB. The other 94 study patients (58.7%) 
were classified as NSTEMI / UA.  
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From the 94 patients that presented with NSTEMI / UA, 11 patients (11.7%) had a 
normal ECG, 6 patients (6.4%) had ECG features of a RBBB, 44 patients (46.8%) 
had ST segment depression and 61 patients (64.9%) had T wave inversion on their 
ECG. 
 
From the study population, 35/160 patients (21.9%) had significant Q waves, 
suggesting previous or established STEMI. Eleven of these were found in patients 
diagnosed with acute NSTEMI / UA, suggesting previous STEMI.   
 
4.6.8 Laboratory findings 
Table 7: Selected laboratory findings of study patients  
Laboratory Finding N % 
 
Elevated Troponin T 103 64.4 
 
Elevated Creatine Kinase – Muscle Band (CK-MB) 86 53.8 
      Missing data 8 5 
 
Elevated Creatinine 28 17.5 
 
Anaemia (Haemoglobin < 12 mg/dl) 12 7.5 
 
Elevated Total Cholesterol 46 28.8 
       Missing data 6 3.8 
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Table 7 summarises selected laboratory findings of all the study patients. The 
highest recorded value during the first twelve hours of presentation was included. 
One hundred and three patients (64.4%) had elevated troponin T, 86 patients 
(53.8%) had elevated CK-MB, 28 patients (17.5%) presented with elevated 
creatinine, 12 patients (7.5%) presented with anaemia (haemoglobin < 12 mg/dl) and 
46 patients (28.8%) presented with elevated total cholesterol. 
 
All of the 66 patients (41.3%) with ST segment elevation / presumably new LBBB 
had elevated troponin T within twelve hours of presentation. Thirty-seven (23.1%) 
patients without ST segment elevation had raised troponin T and were diagnosed as 
NSTEMI. Therefore 57/160 patients (35.7%) were diagnosed as UA.   
 
 
Figure 8: Pie chart describing the proportion of study patients that presented 
with the various subcategories of ACS 
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4.7 Risk factors for ACS of study patients  
 
The prevalence of previous acute coronary syndrome (ACS) was 27.5% (44/160), 
family history 18.1% (29/160), previous heart surgery 6.3% (10/160), obesity (BMI > 
30 kg/m2) 28.1% (45/160), hypercholesterolemia 28.8% (46/160), diabetes 26.3% 
(42/160), hypertension 47.5% (76/160), and renal failure 16.9% (27/160). 
Hypertension was the most frequent risk factor among the study patients. Only 6% of 
study patients had documented HIV test results therefore it was not included in the 
study.    
 
4.8 Age of study patients 
 
The ages of the study patients ranged from 17 to 87 years with a mean age 
(standard deviation (SD)) of 55.8 (12.8) years. The age distribution is shown by the 
frequency histogram in Figure 9. 
 
Figure 9: Frequency histogram describing age distribution of study patients  
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After categorising the ages into age groups, the distribution is shown in Figure 10. 
 
Figure 10: Frequency histogram for age group categories of study patients 
 
The majority of the patients were in the age group of 45-54 years (50/160, 31.3%), 
followed by the 55-64 year age group (43/160, 26.9%), and then the 35-44 year age 
group (22/160, 13.8%). More than three-quarter (76.4%) of study patients were aged 
˂ 65 years; and those aged ≥ 65 years were only approximately 24%. 
 
4.9 Sex of study patients 
 
The majority of study patients were male (90/160, 56.25%). 
 
4.10 Race of study patients 
 
The majority of the study patients were Asian (103/160, 64.4%) and there were more 
black patients (36/160, 22.5%) than white patients (21/160, 13.1%) as shown in 
Table 8.  
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Table 8: Frequency distribution for race of study patients  
Race N % 
Asian 103 64.4 
Black 36 22.5 
White 21 13.1 
Total 160 100 
 
 
4.11 Socio-economic and behavioural characteristics of study patients 
 
The majority of the study patients were unemployed (98/160, 61.3%), urban resident 
(143/160, 89.4%), referred from private practice (37/160, 23.1%), not alcohol users 
(137/160, 85.6%), and not smokers (88/160, 55.0%). 
 
4.12 Management of study patients 
 
4.12.1 Initial management 
All study patients were initially administered oxygen. The majority were given aspirin 
(145/160, 90.6%) and nitrates (145/160, 90.6%). The majority of study patients were 
also given enoxaparin and clopidogrel (141/160, 88.1%), whilst less than half of the 
patients (69/160, 43.3%) were given morphine. 
 
4.12.2 Early reperfusion therapy 
Sixty-two patients (38.8%) presented with ST segment elevation and 4 patients 
(2.5%) presented with presumably new LBBB. Therefore 66 of the study patients 
were considered for early reperfusion therapy. However, only 65% (43/66) of these 
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patients received early reperfusion therapy. The other 23 patients (35%) presented 
beyond the cut off time period and were therefore not considered for early 
reperfusion therapy. Of the 43 patients that were eligible for early reperfusion 
therapy, 40 patients (93.0%) received thrombolytic therapy (2 patients (5.0%) 
received alteplase and 38 patients (95.0%) received streptokinase). Due to timing 
and the long distance to the nearest PCI facility, primary PCI was not considered for 
any of these patients. The other three patients had contra-indications to the use of 
thrombolytic agents and were hence transferred emergently to the PCI facility. Seven 
of the forty patients that received thrombolytic agents (19.5%), did not have 
appropriate resolution of the ST segments. All of these patients were transferred to 
the PCI facility for rescue PCI.  
 
As per Ladysmith Provincial Hospital protocol, all patients presenting with ACS 
(STEMI / NSTEMI / UA) must be referred to an appropriate facility for coronary 
angiography in order to delineate coronary anatomy. Over the entire study period, 
eight patients (4.1%) referred from Ladysmith Provincial Hospital for coronary 
angiography underwent coronary artery bypass grafting (personal communication 
with cardiology ward staff at Grey’s Hospital). 
 
4.13 Outcomes of study patients  
 
4.13.1 Clinical deterioration requiring ICU 
About 26.3% (42/160) deteriorated clinically and were transferred from the medical 
ward to the ICU. 
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4.13.2 Length of hospital stay 
 
Figure 11: Frequency histogram for length of hospital stay of study patients  
 
The median number of days in hospital was 3 days and ranged from 1 to 16 days. 
The mean (SD) number of days spent in hospital was 3.6 (2.0) days. Figure 11 
shows the frequency histogram for length of hospital stay. The majority of patients 
stayed in hospital for three days (49/160, 30.6%).  
 
4.13.3 Time to clinical stability 
Clinical stability was defined as the first day that patients met two or more of the 
following criteria: resolution or improvement of symptoms, systolic blood pressure 
(SBP) ˃ 90 mmHg, heart rate 50 – 100 beats per minute and Killip class ˂ II (i.e. no 
clinical evidence of left ventricular failure).113 Time to clinical stability was calculated 
by subtracting the date of admission from the first date the patient achieved clinical 
stability.  
 
0
1
0
2
0
3
0
4
0
5
0
F
re
q
u
e
n
cy
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Number of days in Hospital
 
 
51 
Table 9: Frequency distribution table for number of days to clinical stability of 
study patients 
Time to clinical stability (in days) N % 
1 42 31.6 
2 59 44.4 
3 23 17.3 
4 5 3.8 
5 2 1.5 
7 2 1.5 
Total 133 100 
 
The frequency distribution of time to clinical stability (in days) is shown in Table 9. 
The median number of days to clinical stability for 133 of the study patients was 2 
days and ranging from 1 to 7 days. The mean (SD) number of days to clinical 
stability was 2.1 (1.1). The majority of the study patients achieved clinical stability 
within 2 days (101/133, 75.9%). The other 27 patients either demised or were 
transferred to the referral centre prior to achieving clinical stability. 
 
4.13.4 Death 
A total of 13 study patients died prior to hospital discharge (8.1%, 13/160). 
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CHAPTER 5 
DISCUSSION 
 
This was a retrospective, cross-sectional, hospital-based study of 160 consecutive 
patients with accessible medical records who presented to the Ladysmith Provincial 
Hospital ED. Difficulty in retrieving medical records and extracting data from medical 
records were some of the constraints of the study.  
 
5.1 Frequency of ACS presentation  
 
A total of 189 patients presented with ACS to the Ladysmith Provincial Hospital ED 
over the study period. This is assuming that the 29 patients for whom no medical 
records could be found had a final hospital discharge diagnosis of ACS. These 189 
patients presented from 1 November 2009 to 31 May 2013, a period of 43 months. 
This represents a frequency of approximately 53 patients per annum. The known 
false positive and false negative diagnosis rates of ACS at the Ladysmith Provincial 
Hospital ED over the study period was 4.1% and 1.9% respectively. However this 
does not account for patients who may have been misdiagnosed or prematurely 
discharged from the ED. In large volume hospitals in Canada, an average frequency 
of approximately 24 patients per year presenting with ACS was reported.33 The 
ACCESS South African study reported an average frequency of 22 patients per 
annum.57  These reported figures represent less than half of that found in this study. 
The higher frequency of ACS reported in this study, when compared especially to the 
South African cohort of the ACCESS study, is concerning and needs to be further 
investigated with regards to population risk factor control measures and possibly 
genetic and environmental factors. In contrast, another study reported a frequency of 
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255 patients per annum (22 patients per month).115 This is about 5 times higher than 
findings from this study. 
 
5.2 Clinical stability of patients on presentation 
 
The majority of patients enrolled in the study had a normal GCS of 15/15 (98.75%). 
The median systolic BP was 122 mmHg and ranged from 66 mmHg to 230 mmHg. 
The overall median diastolic BP was 83.5 mmHg and ranged from 43 mmHg to 140 
mmHg. The overall median heart rate was 85 beats per minute and ranged from 38 
beats per minute to 147 beats per minute. The overall median respiratory rate was 
20 breaths per minute and ranged from 12 breaths per minute to 40 breaths per 
minute. A study reported a median systolic BP of 130 mmHg and ranged from 118 
mmHg to 152 mmHg, a median diastolic BP of 80 mmHg and ranged from 70 mmHg 
to 86 mmHg. The same study also reported a median heart rate of 71 beats per 
minute and ranged from 60 beats per minute to 80 beats per minute, and a median 
respiratory rate of 20 breaths per minute and ranged from 18 breaths per minute to 
21 breaths per minute.115 These results are very similar to findings from this study. 
 
5.3 Presenting clinical features   
 
5.3.1 Chest pain 
Approximately three quarters of the study patients (74.4%) presented with typical 
chest pain.56 In a study, 70.8% of patients presented with typical chest pain.80 
Another study reported 83% of patients that presented with typical chest pain.54 
Nearly one quarter (24.6%) of the study patients had an atypical presentation. The 
reported incidence in other studies was between 33.3% and 47%.3,54,84-86 Of all the 
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study patients with atypical presentations, 9.4% presented without chest pain (silent 
presentation). This was similar to 8.4% reported by Brieger et al, in the GRACE 
study.58 Stern et al116, Canto et al117 and Milner et al118 reported incidence of 21.7%, 
26.5% and 30% respectively.  Dyspnoea was the most common symptom (66.7%) in 
patients with no pain in this study. Dyspnoea was also reported to be the most 
common presenting symptom in patients without chest pain (49%) in the GRACE 
study.58 
 
5.3.2 Associated symptoms 
Most of the study patients presented with dyspnoea as the commonest associated 
symptom (19.5%). Dyspnoea was also reported as the most common associated 
symptom (51%) by Arslanian-Engoren and colleagues in a study conducted on 
women and men presenting with ACS.56 Nausea alone or associated with vomiting 
represented the second most common associated symptom of the study patients 
(18.8%). This was in contrast with the GRACE study which found that diaphoresis 
was the second most common symptom (26.2%) on presentation.58 Radiation to the 
left arm was reported in 31.3% of study patients. This was similar to 25 % reported 
by Arslanian-Engoren et al.56  
 
5.3.3 Cardiogenic shock and cardiac failure 
Approximately 4% of the study patients presented with cardiogenic shock, which was 
similar to other studies.54,58 A significant proportion of the study patients presented 
with cardiac failure (19%). The reported incidence in other studies was between 
5.8% and 26%.56,92,93  
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5.3.4 ECG findings 
The majority of the study patients presented with NSTEMI / UA (58.8%), which was 
similar to the ACCESS study (59%)57 and the study conducted in 41 countries by 
Lemos et al (60%).52 Likewise, 38.8% of study patients presented with STEMI. The 
above two studies found a similar incidence of 41% and 40% respectively.52,57 The 
reported incidence in other studies was between15% and 27%.53,99 
 
The prevalence of ST-segment elevation / presumably new LBBB among study 
patients was 38.8%. The prevalence for ST-segment elevation in this study is about 
three times higher than the 12.7% reported in the non-American cohort of the 
PURSUIT study.100 Amongst patients that presented with NSTEMI / UA, 46.8% had 
ST segment depression and 64.9% had T wave inversion on their ECG. The non-
American cohort of the PURSUIT study also reported a 56.2% prevalence of ST 
segment depression and a 51.4% prevalence of T wave inversion.100  
 
5.3.5 Laboratory findings 
Almost two thirds of study patients tested troponin positive (64.4%), which was 
similar to the 69.3% reported by Mukherjee and colleagues in a study on the impact 
of combination evidence-based medical therapy on mortality in patients with ACS.53 
The reported incidence by Antman and colleagues was 95% in the TIMI IIIb study119 
and was 31% in the study by Goncalves et al.120   
 
5.4 Risk factor assessment  
 
The overall comorbidity and risk factors associated with ACS in this study reflected 
those described in the literature. HIV as a risk factor could not be analysed in this 
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study given that most files did not have HIV result recorded. A study has reported 
AMI rates of 11.13 per 1000 patient-years for HIV and 6.98 per 1000 patient-years 
for non-HIV.72  
 
Almost half of the study patients (47.5%) had hypertension. Four other studies had a 
reported prevalence of hypertension of 34%55, 50%52, 50.8%54 and 75%.56 
Hypercholesterolemia was the second most frequent comorbidity and accounted for 
30.6% of study patients. The reported incidence in other studies was 16%,55 30.5%54 
and 59%.56 Obesity was the third most frequent comorbidity and found in 28% of 
study patients. This was similar to 25% reported by El-Menyar et al.54 About 26% of 
study patients had diabetes mellitus. Similar findings were reported in the ACCESS 
study (23.9%) 57 and in the Grace (24.3%) study.58 other studies reported figures of 
16%55 and 38%.54 About seventeen percent (16.9%) of patients had renal failure, 
which was similar to 15% reported by El-Menyar and colleagues54 and 17.4% 
reported by Meier and colleagues in the University of Michigan study.61 
 
About a quarter (27.5%) of study patients had known prior CAD. The reported 
incidence in other studies was 26.9%55, 37%80 and 43.7%.54 Only 18.1% of the study 
patients had a positive family history of CAD, which was similar to 21% reported by 
Lemos et al.52 This was higher than 13% reported by El-Menyar et al in the Gulf 
RACE study,54 but lower than 31.2% reported by Gurm et al.55 Only 6.3% of patients 
had previous heart surgery (CABG), which was similar to 7.1%  reported by Lincoff 
and colleagues in the non-US cohort of the PURSUIT study.100 Other studies 
reported a prevalence of between 4% and 13%.52,58 
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5.5 Demographic characteristics 
 
The mean age was 55.8 ± 12.8 years, which was similar to the mean age of 58.0 ± 
12.1 years reported in the ACCESS study.57 Matetzky et al also reported a similar 
mean age of 57 ± 12.8 years in their acute myocardial infarction study conducted in 
an Israeli population.121 In contrast, Eagle et al reported a higher mean age of 65 ± 
13 years in the validated prediction model of all forms of ACS study, which was 
conducted in 14 different countries.92 Gonҫalves and colleagues also reported a 
higher mean age of 63.4 ± 10.8 years.120 In this study, the youngest patient was 17 
years old and the oldest was 87 years old. A similar finding of 18 – 90 years was 
reported in the study by Bhattacharyya and colleagues.122 Matetzky and colleagues 
reported a range of 28 – 74 years in their study.121 Arslanian-Ergoren at al56 and 
Schamroth et al57 also reported the youngest patient in their study as 17 years.   
 
The overall sex distribution in this study was 56% males and 44% females. Amongst 
Asians, about two thirds were male whereas amongst Blacks and Whites more than 
half were female. Mukherjee and colleagues reported an overall gender distribution 
of 63% male and 37% female.53 The ACCESS study reported an overall 76% male 
and 24% female gender distribution.57 Another study found the gender distribution to 
be 75% male and 25% female.52 The higher proportion of females amongst Blacks 
and Whites in this study is a concern and needs to be further investigated.  
 
Although Asians only comprise about 2.5% of the South African population,123 the 
majority of the study patients with ACS were Asian (103/160, 64.4%). There were 
more Black patients (36/160, 22.5%) than White patients (21/160, 13.1%). In the 
United States of America, a study reported the majority of patients with ACS were 
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white (75%), followed by black patients (7%), and Asian patients represented only 
3%.93 Another study also found Asians to be at higher risk for CAD.32 The alarmingly 
high prevalence of ACS amongst Asians in this study is concerning and warrants 
further investigation. Vigorous education programmes, modifiable risk factor control 
measures and possibly genetic predisposition testing need to be promulgated at a 
governmental level.  
 
5.6 Socio-economic and behavioural characteristics 
 
The majority of patients (89.4%) came from urban areas; only 10.6% came from rural 
areas. This is consistent with a rapid change in the spectrum and pattern of 
cardiovascular diseases and risk factors associated with urbanisation in African 
countries.64 This reaffirms the epidemiologic transition in South Africa.11 A substantial 
proportion of study patients (61.25%) were unemployed. This rate of unemployment 
is substantially high given the current unemployment rate of 25.6% in South Africa as 
per Statistics South Africa’s second quarter year 2013 report124 and also given the 
fact that more than three-quarters (76.4%) of study patients were aged ˂ 65 years. 
The high unemployment rate in this study may be partly due to the 24% of patients 
who were 65 years and older, most of whom were retired. It is also likely that most 
people that are employed have medical insurance and are more likely to present to 
private health care facilities. Despite being high, the unemployment rate was similar 
to 60.6% reported by Alter et al in a Canadian study on socioeconomic status and 
mortality after acute myocardial infarction33 and 66% reported by Pitsavos et al.125 It 
was lower than 48.7% reported by Kronish et al.126  
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Forty five percent of study patients were smokers, which was similar to the 44% 
reported in the ACCESS study.57 Other studies reported an incidence of 41%52 and 
63%.53 Only 16.4% of patients admitted to alcohol use. Hansen et al in a Danish 
study on alcohol intake and acute coronary syndrome reported a prevalence of 
10.2%.46 
 
5.7 Management  
 
Eighty eight percent of patients in this study were administered both enoxaparin and 
clopidogrel. The ACCESS study reported that 73.3% of all patients in South Africa 
received low molecule weight heparin (enoxaparin).57 Other studies reported 
frequencies of 41.7% and 88.4%.120,61   
 
Approximately two-third of eligible patients (65%) underwent early reperfusion 
therapy, which was similar to the 70% reported by Eagle et al in the Australian, 
Canadian, New-Zealand and European cohorts of the GRACE study.99 Thirty five 
percent of patients who potentially could have received early reperfusion therapy 
were deemed not eligible. These patients presented to the Ladysmith Provincial 
Hospital ED after the cut-off time for early reperfusion and all of them had 
established Q waves on presentation. They were all transferred to the referral 
cardiology unit. The ACCESS study reported a similar percentage of patients (39%) 
who did not receive early reperfusion therapy.57, 127 Of the patients that underwent 
early reperfusion therapy, 93% received thrombolysis. The GRACE study reported 
that 49% in Europe, 67% in Australia and New Zealand and 31% in Canada 
underwent thrombolysis.99 A much higher percentage of patients in this study 
received thrombolytic therapy as Ladysmith Provincial hospital does not have a PCI 
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facility and also the closest PCI facility is a distance away. Only 10 patients (15.2%) 
were referred early to the PCI referral centre. Three patients had contra-indications 
to the use of thrombolytic agents and seven patients required rescue PCI.  
 
Although alteplase and other newer tissue plasminogen activator agents are 
regarded as thrombolytic agents of choice in the USA2 and Europe,106 the majority of 
patients (94%) who underwent thrombolytic therapy in this study received 
streptokinase and only 6% were thrombolysed with alteplase. Alteplase does have 
marginal benefits in terms of side effects and speed of onset, but is associated with 
higher bleeding rates and cost when compared to streptokinase.128 Alteplase and the 
other newer tissue plasminogen activator agents  are not widely available at the 
Ladysmith Provincial Hospital. All patients treated with streptokinase were 
premedicated with hydrocortisone and promethazine prior to thrombolysis so as to 
minimise the risk of anaphylactic reactions.     
 
Over the entire study period, eight patients (4.1%) referred from the Ladysmith 
Provincial Hospital for coronary angiography underwent coronary artery bypass 
grafting (personal communication with cardiology ward staff at Grey’s Hospital). 
Other studies reported CABG figures of 3.63%61, 14.6%57 and 18.3%.120  
 
5.8 Outcomes 
 
The overall median time to clinical stability of study patients was 2 days, with a range 
between 1 and 7 days. The first and second SYMPHONY studies have reported 
median times to clinical stability of 3.6 days (with a range between 2.2 and 5.1 days) 
and 3.7 days (with a range between 2.6 and 5.5 days) respectively.113 About 26.3% 
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of study patients deteriorated clinically and were transferred from the medical ward 
to the ICU. There were no data in the literature to compare step-up to the ICU of 
patients who had deteriorated. The overall median number of days spent in hospital 
(length of hospital stay) was 3 days. This was slightly more than the 5 days reported 
by the American cohort of the PURSUIT study.100 The Swiss study found the median 
length of hospital stay post ACS to be 8 days,112 whereas in the non-American 
cohort of the PURSUIT study, the median length of hospital stay was 10 days.100 The 
shorter length of hospital stay reported in this study is probably due to the fact that 
patients at Ladysmith Provincial Hospital are generally discharged earlier due to 
patient overcrowding and bed pressures.  
 
There was an in-hospital mortality rate of 8.1%, which is slightly more than 6.9% 
reported by Meier et al in a University of Michigan study on ACS patients61  and 6.3% 
reported by Arora in a ACS study conducted in the North America.114 Overall in-
hospital mortality rates of 5% and 5.3% were reported respectively by Brieger et al in 
the GRACE study58 and by Brilakis et al in the quality of care for ACS patients with 
known atherosclerotic disease study.93 The overall in-hospital mortality rate in the 
Gulf RACE study was 3.27%.54 Even though Ladysmith Provincial Hospital does not 
have PCI and CABG capacity, the mortality rates were not much higher than those 
reported in first world countries. This may reaffirm that thrombolytic therapy may be 
as effective as other forms of reperfusion therapy. Ladysmith hospital also adheres 
strictly to the American Heart Association guidelines on the management of ACS and 
is also in constant consultation with a team of highly skilled cardiologists at its 
referral hospital.  
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5.9 Limitations of the study 
 
Clearly, a retrospective analysis holds less weight than a prospective study. As such 
this study is subject to known limitations regarding spurious findings, missing data 
and conflicting data.  
 
It is important to emphasise that because of the nature of the presentation of ACS 
especially in its atypical form, clinicians may fail to even consider the diagnosis of 
ACS, resulting in under-diagnosis and under-reporting of the actual frequency of 
ACS. In this study ED, ICU, high care and medical ward registers were screened to 
identify patients presenting with ACS that were missed in the ED and later diagnosed 
in these wards. The known false positive and false negative diagnosis rates of ACS 
at the Ladysmith Provincial Hospital ED in this study was 4.1% and 1.9% 
respectively. However, this study does not account for patients who may have been 
misdiagnosed or prematurely discharged from the ED.  
 
Electrocardiograms are routinely carried out on all patients presenting to the 
Ladysmith Provincial Hospital ED with a complaint of pain anywhere from the nose to 
the pubic symphysis and also on all patients older than 45 years of age. This would 
also have minimized the chances of missed ACS. However some patients with 
atypical presentation of UA / NSTEMI and to a lesser extent STEMI may still not 
have been recognized and erroneously discharged from the ED. Therefore, it is 
recognized that the reported frequency of ACS presenting to the ED in this study 
may be underestimated. 
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Important data pertaining to HIV status, ED time of evaluation, the time of onset of 
symptoms, or time to reperfusion therapy were not documented in the majority of 
study patients. Likewise, medical records on most of patients referred to Grey’s 
hospital for further management were not available. Medical records of 29 patients 
(14.7%) could not be accessed.  
 
Moreover, this is a single centre study conducted in a public hospital in a medium 
sized town of South Africa. Consequently, the findings of this study may not be 
applicable to the private setting or to other geographic parts of South Africa.  
 
There are also some limitations pertaining to the reviewing of medical records in 
general that are relevant to this study.129 Firstly, the researcher, who was not blinded 
to the study aims and objectives, abstracted all the data from the medical records. 
Secondly, the researcher did not receive formal training or certification in methods of 
data abstraction. The researcher did however spend about four hours researching 
various methods of data collection prior to the process of collecting data. Thirdly, 
although inter-rater reliability was assessed, the abstractors (researcher) 
performance was not formally monitored. 
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CHAPTER 6 
CONCLUSION 
 
Despite the many limitations of this retrospective study, valuable information has 
been gained. Firstly, the higher frequency of ACS reported in this study, when 
compared to other similar studies, is concerning. Secondly, the alarming prevalence 
of ACS amongst Asians in this study population is also concerning. Both of these 
warrant further investigation. Vigorous education programmes, modifiable risk factor 
control measures and possibly genetic predisposition testing must be promulgated at 
a governmental level. Thirdly, although Ladysmith Provincial hospital is situated in a 
low / middle-income country and does not have PCI and CABG capacity in close 
proximity, the mortality rate and length of hospital stay are comparable to those 
reported in high-income countries. 
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APPENDIX 2  
Patient Data Collection Sheet 
 
Patient identification number (PIN):   Patient hospital number: 
Demographic data 
 
Age: Sex: M / F 
Race: Black Asian White Coloured Other: 
Socio-economic status  
Employment employed unemployed 
Residence Urban Rural International  
Referring centres Self Clinics 
Peripheral  
hospital  Private Other 
Alcohol use  Yes No 
Risk factors 
Smoking Yes No 
HIV status positive negative Unknown 
for HIV positive on HAART   not on HAART   
Previous ACS Family history Previous heart surgery 
Obesity (weight / BMI) Hypercholesterolaemia Diabetes 
Hypertension Renal failure Other (specify) 
ED date and time of evaluation   Date Time 
Vital signs on presentation 
SBP DBP HR RR 
GCS on presentation 
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Presenting symptoms and signs  
Typical chest pain Atypical chest pain 
Associated symptoms (specify) 
 
 
 
No chest pain Radiation of pain (specify) 
Signs of cardiogenic shock Signs of cardiac failure 
ECG findings 
Normal ECG  
ST elevation  
ST depression  
Presumably new LBBB   
RBBB   
T inversion   
Q wave   
Other  
Laboratory findings 
Cardiac biomarkers (specify time from onset of symptoms): 
     Troponin T: 
     CK-MB: 
Urea and creatinine: Haemoglobin: 
Total cholesterol: 
Echocardiography done: Yes No  
If yes (echocardiographic features of ACS, e.g. wall motion abnormalities):     Y / N 
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Patient management 
Site of care Length of stay 
ED  
ICU  
High care  
Medical ward  
Other significant events: e.g. cardiac arrest / CPR / defibrillation 
Initial treatment (specify time from presentation) 
Aspirin   Nitrates  
Oxygen  Morphine  
Adjunctive therapy (specify) 
Reperfusion therapy:  Y / N 
Thrombolytics (specify agent) 
PCI 
CABG surgery 
Patient outcomes 
Step-down 
Step-up 
Time to clinical stability 
Death  
  
 
 
 
